Treatment with oral semaglutide (Rybelsus) significantly improved motivation measures in patients with major depressive ...

The use of 42 mg lumateperone combined with antidepressant therapy was linked to significantly reduced severity of depression and anxiety, as well as greater response and remission rates, and was ...

Definium Therapeutics (NASDAQ:DFTX) is approaching what Chief Executive Officer Rob Barrow described as an “incredibly exciting time,” with pivotal data expected this year for DT120, the company’s pro ...

A study published in the Journal of Affective Disorders proposes a novel, fully automated artificial intelligence (AI) algorithm leveraging ExtraTrees (ET) forests to distinguish patients with major ...

The largest and most ethnically diverse study of its kind has identified 697 genetic variants linked to major depressive disorder (MDD). The research also highlights potential therapies for ...

Credit: Otsuka. At this time, the product is available to patients for a discounted price of $50; the full price is $200. Rejoyn ™, the first prescription digital therapeutic cleared for the treatment ...

Women with MDD who did not use antidepressants had more than twice the risk of breast cancer recurrence as women without MDD. Women with breast cancer who also have major depressive disorder (MDD) ...

Please provide your email address to receive an email when new articles are posted on . Spravato is the first monotherapy for adults with major depressive disorder who had an inadequate response to at ...

Zachary Contreras of Sharp Health Plan discusses how predictive tools, artificial intelligence-driven analytics, and digital monitoring can help identify treatment-resistant depression early, enabling ...

Please provide your email address to receive an email when new articles are posted on . At day 43, lumateperone led to greater improvement vs. placebo on all metrics. Treatment-emergent adverse events ...